ERBB2 and breast carcinoma: In order to seek the clinical relevance of ITPKC expression, we performed survival analyses of the whole breast cancer cohort (Whole), and ER-positive/HER2-negative, TNBC and HER2-positive subtypes by Kaplan–Meier analyses of overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) in the TCGA and DFS alone in the GSE25066 cohort (Figure 2B).